• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Amgen

Amgen

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Amgen Shares Still Look Undervalued

    The firm’s recent pipeline productivity should help stabilize its wide economic moat, writes Morningstar’s Karen Anderson.

  2. European Commission Approves Amgen's Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Metastatic Colorectal Cancer

    European Commission Approves Amgen's Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Metastatic Colorectal Cancer

  3. FDA Approves Amgen's Heart-Failure Drug Corlanor

    FDA Approves Amgen's Heart-Failure Drug Corlanor

  4. Why only Apple may be able to lift the S&P 500 out of limbo

    Why only Apple may be able to lift the S&P 500 out of limbo

  5. UPDATE: Why only Apple can lift this market out of limbo

    UPDATE: Why only Apple can lift this market out of limbo

  6. UPDATE: A key technical level eludes the S&P 500 and only Apple can help

    UPDATE: A key technical level eludes the S&P 500 and only Apple can help

  7. UPDATE: Chipotle shares fall on slowing sales

    UPDATE: Chipotle shares fall on slowing sales

  8. UPDATE: Facebook slips following results; AT&T gains on earnings beat

    UPDATE: Facebook slips following results; AT&T gains on earnings beat

  9. UPDATE: Angie's List soars on earnings; McDonald's sets date to roll out turnaround

    UPDATE: Angie's List soars on earnings; McDonald's sets date to roll out turnaround

  10. UPDATE: Facebook, McDonald's, Coca-Cola in focus Wednesday

    UPDATE: Facebook, McDonald's, Coca-Cola in focus Wednesday

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.